Utah Medical Products (UTMD): 0 Analysts, 30% Net Margin

Utah Medical Products sells obstetrics and neonatal medical devices. It has operated at a net income margin between 29% and 34% across five fiscal years — and posted 30.7% in 1H 2026 even as revenue declined 12.3% year-over-year. It has [FMP] 0 formal analyst estimates . The connection between those two facts is economic: a ~$222 million market cap produces a position size too small to justify sell-side research at most institutional desks, and without formal coverage, the revenue decline narrative from FY2022 to today has run largely unchallenged. The market has been looking elsewhere.

Coverage Gap

The gap is an economics problem, not a float problem. Institutional investors hold positions in UTMD — Brandes Investment Partners at 11.0%, Renaissance Technologies, Dimensional, Vanguard, and BlackRock among them. [SEC] DEF 14A (2026) — 5%+ Beneficial Holders The issue is that sell-side analysts get assigned to cover companies where their clients can build positions large enough to matter to a portfolio. At ~$222 million market cap, UTMD falls below that threshold for most mid- and large-cap desks. Even a concentrated value investor at 11% doesn't generate enough secondary trading to create economic incentive for a sell-side desk to initiate. The result: no formal analyst estimates, no systematic earnings revision cycle, no institutional attention anchoring the price to fundamentals.

The gap is self-reinforcing. Without coverage, incremental events — an OEM customer exit, a guidance revision, a litigation update — go unanalyzed and uncontextualized. UTMD's ongoing buyback program has retired 11.5% of shares since FY2021 — narrowing the float in a direction that compounds the coverage economics. [FMP] 0 analyst estimates

Business

UTMD makes single-patient medical devices for two clinical settings: labor and delivery, and neonatal intensive care. Its catalog spans obstetrics (intrauterine pressure catheters, fetal scalp electrodes, vacuum delivery systems), neonatal care (umbilical catheter trays, pressure monitoring), gynecology and urology (electrosurgery instruments), and blood pressure monitoring (the Deltran family of disposable pressure transducers). [SEC] 10-K Item 1 — Business

The Filshie Clip System accounts for approximately 26% of FY2025 revenue. Developed in the 1970s and acquired through UTMD's 2011 purchase of Femcare Holdings Ltd (UK), the titanium clip is placed on fallopian tubes during laparoscopic procedures for permanent female contraception. Per the 10-K, it has been "implanted in six and a half million women worldwide during the last 43 years" and has "empirically been proven to be the safest and most effective tubal occlusive device." [SEC] 10-K — Filshie Clip System UTMD secured exclusive U.S. distribution rights in 2019 from CooperSurgical.

UTMD Ltd, a wholly-owned subsidiary in Athlone, Ireland, manufactures devices for international distribution. The Ireland subsidiary is taxed at 12.5% on manufactured exports (versus 25% on Irish domestic sales). [SEC] 10-K — UTMD Ltd Ireland Filshie devices imported into the U.S. from Ireland became subject to a 15% tariff in 2026; the company is shifting other devices previously exported from the U.S. to Ireland in order to partially offset this through lower U.S. income taxes.

The company's 140 full-time employees generate $38.5 million in FY2025 revenue and $11.3 million in net income. [SEC] 10-K — Employees Revenue per full-time employee exceeds $275,000; net income per employee exceeds $80,000.

Moat / Mispricing

The mispricing thesis rests on a cause-and-effect: the revenue decline from $52.3 million (FY2022) to the current trajectory is primarily not a core product problem.

Between FY2022 and FY2025, UTMD supplied pressure sensors and accessories to PendoTECH, an OEM customer in the biopharmaceutical manufacturing sector. At peak, PendoTECH represented $11.6 million — 22% of total revenue. As PendoTECH's demand fell, its contribution declined: $2.7 million in FY2024, $0.4 million in FY2025. UTMD ceased supply after the first half of 2025. PendoTECH revenue is zero beginning in FY2026. [SEC] 10-K — OEM Sales

FY2026 adds a further headwind: blood pressure monitoring kit sales through a China-based independent distributor (approximately $2.1 million in FY2025) are also at zero. Combined, FY2025 revenue from these two customer relationships was $2.5 million — and will not recur in FY2026. Management planned to replace this volume with new product sales, with the 10-K qualifying that outlook with "substantial uncertainty." [SEC] 10-K MD&A — 2026 Outlook

The July 23, 2026 earnings release provided the first hard data on that replacement plan: 1H 2026 revenue was $17.3 million versus $19.7 million in 1H 2025 (-12.3%). New biopharma customers contributed $211 thousand in 1H 2026 — well below the volume needed to offset the lost relationships. Management revised FY2026 guidance to a 10–13% revenue decline versus FY2025, implying full-year revenue of approximately $33.5–34.7 million. Net income margin in 1H 2026 was 30.7%, essentially unchanged from the prior year's 31.0%. [SEC] 8-K — Q2 2026 Earnings Release

The 1H 2026 bifurcation is the thesis-defining data point. Domestic Filshie Clip sales rose 10.7% year-over-year — a single-geography improvement that follows a 7% worldwide Filshie decline in FY2025, providing mixed but net-positive evidence for the clinical franchise. The new product ramp is behind plan. This distinction matters: one is evidence about business quality; the other is evidence about execution pacing. The 2H 2026 data will determine whether the pacing is a delay or a structural failure.

Screen for UTMD and what appears is a 35% revenue decline from FY2022 to the FY2026 guidance midpoint, with EPS trajectory following. What that screen does not show is the margin. The structural durability of 29–34% net income margins across five fiscal years of revenue pressure reflects product entrenchment: hospitals standardize on obstetrics and neonatal device procedure kits for years at a time, clinical staff trained on specific instruments do not adopt alternatives without compelling evidence, and the Filshie Clip's six-million-patient history represents accumulated physician familiarity that takes years to displace.

Capital Allocation

Since 1992, UTMD has returned $246 million to shareholders: $156 million in share repurchases and $90 million in dividends. The company that exists today — worth approximately $222 million in market cap — has returned more than its current value to shareholders over the past three decades. [SEC] 10-K — Share Repurchases and Dividends

In FY2025, UTMD repurchased 148,935 shares for $8.355 million and paid dividends of $1.22 per share, totaling $4.0 million. Combined capital return of approximately $12.4 million on $14.7 million in operating cash flow. Cash and investments improved to $87.5 million at June 30, 2026. Share repurchases in 1H 2026 were minimal — $206K versus $6.7M in 1H 2025 — as UTMD preserved capital through the revenue transition. That cash balance equals 39.4% of current market cap and represents nearly six years of operating cash flow at the FY2025 rate. [SEC] 8-K — June 30 2026 Balance Sheet

Kevin Cornwell, President and CEO since December 1992 and Chairman since 1996, holds 5.9% of shares directly. [SEC] DEF 14A (2026) — Security Ownership His daughter, Carrie Leigh, serves on the board as a non-independent director. Combined, directors and executive officers hold approximately 8.0% of shares — a meaningful but not majority stake. Cornwell's 33-year tenure as CEO has coincided with the systematic buyback program: the share count has declined from 3.660 million (FY2021) to 3.240 million (FY2025) — an 11.5% reduction in four years.

Risks

Four failure paths are worth mapping.

Product liability — Filshie Clip. The Filshie Clip is UTMD's only ongoing litigation. A product liability lawsuit alleging clip migration was filed in Texas; the same law firm subsequently recruited plaintiffs across multiple states, resulting in cases filed in 19 federal or state courts. As of March 2026, all cases except those filed in CT state court are expected to be dismissed by summary judgment during 2026; Femcare Ltd. and Utah Medical Products have already been dismissed as defendants in CT. No trials have been held. [SEC] 10-K Item 3 — Legal Proceedings Litigation costs increased by $341K in 1H 2026 versus 1H 2025. [SEC] 8-K — Q2 2026 The Clip's own inventor estimated clip migration rates above 25% (asymptomatic); the 10-K cites a journal figure of 6%. For a product accounting for 26% of revenue and central to the moat argument, trial outcomes or expanded litigation would be the clearest thesis-breaking event.

Technology speed. The Filshie Clip competes implicitly with long-acting reversible contraception — hormonal IUDs and subdermal implants increasingly preferred by patients seeking reversibility. If clinical and cultural preference continues shifting away from permanent tubal occlusion, the addressable market narrows over time. This is a slow structural pressure, not a cliff, but it is directional.

Key-person. Kevin Cornwell has served as CEO and Chairman for 33 years. He is UTMD's largest individual shareholder and the primary architect of its capital allocation discipline. The company has a board succession structure, but a leadership transition — planned or otherwise — would introduce uncertainty that the coverage gap prevents the market from pricing in advance.

TAM and tariff. UTMD's U.S. obstetrics and neonatal markets track domestic birth rates, which have been declining. International expansion through the Ireland subsidiary is the primary offset, but Filshie devices imported from Ireland into the U.S. are now subject to a 15% tariff; the tariff exposure is current, not hypothetical, and the manufacturing shift underway in FY2026 addresses other devices rather than resolving this tariff directly.

Valuation

Based on 1H 2026 EPS of $1.66 and FY2025 EPS of $3.48, trailing twelve-month diluted EPS is approximately $3.28 ($3.48 − $1.86 + $1.66). At approximately $70 per share, UTMD trades at roughly 21× TTM earnings. [FMP] price ~$70

Strip out the cash. At 3.183 million shares outstanding (per the Q2 2026 filing), the $87.5 million cash and investments balance (June 30, 2026) equals approximately $27.50 per share. The operating business is effectively priced at roughly $42.00 per share. At $3.28 in TTM earnings, the ex-cash multiple is approximately 12.8×.

Twelve to thirteen times TTM earnings for a business that has sustained 29–34% net income margins across five fiscal years, carries no debt, and generates operating cash flow reflects the coverage-gap discount — compounded by a fourth consecutive year of declining revenue. Whether that discount is justified depends on whether the new product ramp materializes in 2H 2026 and whether Filshie litigation resolves without a trial.

If domestic Filshie continues growing, litigation resolves favorably, and new product ramp accelerates, the 12–13× ex-cash multiple looks compressed relative to the margin quality. If core clinical revenue also turns negative, or if litigation costs expand materially, the thesis depends on the $87.5 million cash cushion absorbing further pressure while the franchise is reassessed.

Re-rating Catalyst

The most important near-term data point is Q3 2026 earnings (expected October 2026). The 1H 2026 results already provided two key reads: domestic Filshie was healthy (+10.7%) and the new product ramp was well behind plan ($211K from new biopharma clients). Q3 will show whether the ramp is accelerating in the second half — and whether NICU device trends reflect the distributor transition or a broader demand shift.

Longer-term, the coverage gap closes through one of two paths: a formal analyst initiation (which requires sufficient secondary trading volume to make coverage economically viable for a sell-side desk) or per-share value accumulation through buybacks as revenue stabilizes — $87.5 million in cash provides runway for both paths.

The cash position is the thesis's backstop. At $87.5 million against a ~$222 million market cap, UTMD can absorb further revenue softness without a capital raise, continue buybacks through a weak top line, and wait for the new product ramp to materialize — whether on a twelve-month timeline or a longer one.